is a busy week ahead for European healthcare companies and so we decided to look ahead at what is likely to be one of the key reports this week. Nova Nordisk has been on a roller coaster in 2025 with the stock down around 50% year to date. What was once Europe's most valuable company has struggled with growing competition particularly state side.The rise of copycat drugs and a weak pipeline of new products have also dampened expectations. And so the pressure on the stock was so intense that Novo Nordisk dec ...